424B5 filed Jun 10, 2026 at 17:21 ET
Tango Therapeutics is raising approximately $566.5 million in net proceeds through a public offering of 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase 1,833,395 shares. The offering priced at a 4.9% discount to the prior closing price of $31.56, resulting in immediate and substantial dilution of $24.10 per share to new investors. The capital raise follows highly positive Phase 1/2 clinical data for its lead candidate vopimetostat in combination with RAS inhibitors, showing a 92% objective response rate in pancreatic cancer, which positioned the company to advance into Phase 3 development. The proceeds are expected to fund operations into 2030 including a pivotal trial and potential commercialization. The large dilutive offering paired with very strong clinical data creates a mixed signal for the stock.